GATAD1

GATAD1 is a nuclear zinc finger protein that functions as a chromatin-associated transcriptional regulator controlling cell-cycle progression and metabolic gene expression across cardiomyocytes, cancer cells, and endothelial cells (PMID:31286678, PMID:39626862). As a transcriptional activator it drives proliferation: in glioblastoma it promotes CCND1 (cyclin D1) transcription by inducing long-range chromatin architectural interactions at the CCND1 promoter (PMID:31286678), in thyroid carcinoma it activates SRRM2 to sustain proliferation (PMID:36654960), and in ER+ breast cancer it represses p21 to maintain CDK2/4- and RB1-phosphorylation-dependent cell-cycle entry (PMID:37567972). In the heart, GATAD1 acts as a metabolic gene regulator, repressing fatty acid oxidation genes (Acaa2, Acadm) while promoting the glucose oxidation gene Pdha1, and is required for cardioprotection after ischemia-reperfusion injury (PMID:39626862). In cerebral endothelial cells GATAD1 controls CD36 expression and thereby caveolae-mediated transcytosis governing blood-brain barrier permeability after ischemic stroke (PMID:40965809). A homozygous S102P mutation causes aberrant nuclear localization and abnormal nuclear morphology in cardiomyocytes, linking GATAD1 to human dilated cardiomyopathy (PMID:21965549), though cardiomyocyte-autonomous loss alone does not recapitulate this phenotype in mice (PMID:39641830). GATAD1 also physically associates with Rab6 and Rab6-GAP (PMID:18791169), and its own expression is positively regulated by 3' DNA methylation (PMID:24462704).

1. 2008 Medium

   Established the first physical interactions of GATAD1 (ODAG), identifying Rab6 and Rab6-GAP as binding partners and connecting it to an in vivo ocular developmental phenotype.

   Evidence Pull-down with mass spectrometry plus transgenic mouse overexpression

   PMID:18791169

   Open questions at the time

   • Does not establish whether the Rab6 interaction is nuclear or cytoplasmic
   • No link between Rab6 binding and the later transcriptional functions
   • Overexpression phenotype may not reflect endogenous role
2. 2011 Medium

   Placed GATAD1 in the nucleus of cardiomyocytes and linked a human DCM-causing mutation (S102P) to disrupted nuclear localization and morphology, framing it as an epigenetic/chromatin regulator.

   Evidence Immunohistochemistry on human cardiac tissue with homozygosity mapping and exome sequencing

   PMID:21965549

   Open questions at the time

   • Single primary method for the mechanistic claim
   • Does not define molecular target genes
   • H3K4me3 interaction is invoked but not demonstrated here
3. 2014 Medium

   Identified an upstream regulatory input on GATAD1 itself, showing its transcription is positively controlled by 3' DNA methylation.

   Evidence COBRA, bisulfite sequencing, and DNMT inhibitor treatment of JAR cells with expression readout

   PMID:24462704

   Open questions at the time

   • Mechanism by which 3' methylation enhances expression unknown
   • Limited to choriocarcinoma cells
   • No functional consequence for trophoblast biology established
4. 2016 Medium

   Confirmed GATAD1's functional requirement in cardiac maintenance in vivo and revealed dual nuclear and sarcomeric I-band localization.

   Evidence Fluorescent tagging/live imaging and TALEN knockout with cardiac phenotyping in zebrafish

   PMID:28955713

   Open questions at the time

   • Functional role of sarcomeric localization undefined
   • No molecular target genes identified
   • Single model organism
5. 2019 High

   Defined a concrete molecular mechanism: GATAD1 promotes CCND1 transcription via long-range chromatin looping, establishing it as a chromatin architectural regulator driving cell-cycle progression in cancer.

   Evidence ChIP-qPCR, EMSA, 3C, microarray, siRNA knockdown, and orthotopic tumor transplantation in GBM

   PMID:31286678

   Open questions at the time

   • Direct DNA-binding sequence specificity not fully resolved
   • Whether looping is direct or via cofactors unknown
   • Generalizability of the looping mechanism to other target genes untested
6. 2022 Medium

   Extended GATAD1's pro-proliferative role to thyroid carcinoma by placing it transcriptionally upstream of SRRM2.

   Evidence siRNA knockdown, overexpression, and SRRM2 epistasis rescue in thyroid carcinoma cells

   PMID:36654960

   Open questions at the time

   • Whether GATAD1 binds the SRRM2 locus directly not shown
   • No chromatin-level mechanism demonstrated
   • Single cell-type study
7. 2023 Medium

   Showed GATAD1 sustains ER+ breast cancer proliferation by repressing p21, linking its activity to CDK2/4 and RB1 phosphorylation in cell-cycle control.

   Evidence CRISPR synthetic lethality screen, knockdown/overexpression, phospho-Western blot, and p21 rescue

   PMID:37567972

   Open questions at the time

   • Direct vs indirect repression of p21 not resolved
   • DNA-binding site at p21 locus not mapped
   • Single cancer context
8. 2024 High

   Established GATAD1 as a cardiac metabolic gene regulator (repressing FAO genes, promoting Pdha1) required for ischemia-reperfusion cardioprotection, while a parallel study showed cardiomyocyte-autonomous loss is insufficient to cause cardiomyopathy.

   Evidence Cardiomyocyte-specific knockout mice with metabolic/functional phenotyping, dual reporter assays, and TAC/aging stress models

   PMID:39626862 PMID:39641830

   Open questions at the time

   • Reconciliation of the metabolic phenotype with the absence of baseline cardiomyopathy unresolved
   • Whether human DCM requires non-cardiomyocyte contributions unknown
   • Direct binding at metabolic gene promoters not mapped
9. 2025 Medium

   Revealed a cell-type-specific endothelial function: GATAD1 controls CD36 expression and caveolae-mediated transcytosis to regulate blood-brain barrier permeability after ischemic stroke.

   Evidence Endothelial-specific conditional knockout mice with experimental stroke, BBB permeability assays, and CD36/transcytosis analysis

   PMID:40965809

   Open questions at the time

   • Whether GATAD1 binds the CD36 locus directly not shown
   • Mechanism linking transcription to caveolae formation incomplete
   • Single laboratory/model

• How GATAD1 selects target genes and whether its reported H3K4me3 interaction, chromatin looping, and Rab6 binding represent a single unified molecular mechanism across tissues remains unresolved.
• No structural model or defined DNA-binding consensus
• Cofactors mediating chromatin looping unidentified
• Relationship between the Rab6 interaction and nuclear transcriptional roles unknown